Navigation Links
DSM and Crucell Sign Agreement with Bioceros to Serve as Pre-Approved Cell Line Generation Partner of PER.C6(R) Cell Line Proteins
Date:2/10/2009

LEIDEN, The Netherlands, and PARSIPPANY, N.J., Feb. 10 /PRNewswire/ -- DSM Biologics and Crucell N.V. (Euronext, Nasdaq: CRXL; Swiss Exchange: CRX) announced today that they have entered into an agreement with Bioceros B.V. of Utrecht, The Netherlands to join their Vendor Network. Under the terms of the agreement, Bioceros will be a pre-approved cell line generation partner for licensees of the PER.C6(R) cell line located in the European Union.

Karen King, president of DSM Biologics notes, "The growing number of PER.C6(R) licensees requires that we expand the possibilities for our licensees to obtain services like cell line generation. We are confident that Bioceros' excellent experience and service level will provide our European licensees additional options to move their PER.C6(R) programs forward successfully."

Bram Bout, CEO of Bioceros added, "We are honored to achieve the distinction of being the first pre-approved Europe-based cell line generation partner using the PER.C6(R) cell line. The PER.C6(R) technology is recognized throughout our industry as providing important advantages compared to other platforms, including its well developed technology, which allow for short manufacturing timelines and exceptionally high productivity levels with off the shelf available culture media. The selection of Bioceros as a preferred Vendor by DSM and Crucell underscores the high quality of the services that we offer to our customers."

The PER.C6(R) technology platform has been developed for the large-scale manufacture of biopharmaceutical products such as recombinant proteins, including monoclonal antibodies. Compared to conventional production technologies, the strengths of PER.C6(R) technology lie in its excellent safety profile, scalability and productivity under serum-free culture conditions. By employing the PER.C6(
'/>"/>

SOURCE DSM Biologics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. DSM Biologics and Crucell Announce Commercial PER.C6(R) Licensing Agreement with Gedeon Richter
2. DSM and Crucell Announce Another Key Achievement for PER.C6(R) Technology; Scale Up of High-Titer Fed-Batch Process to 250 Liters
3. Debiopharm and Pharmaleads Sign License Agreement for Debio 0827 or PL37 in Treatment of Chronic Pain Conditions
4. Lentigen and Expression Therapeutics Sign Hemophilia Co-Development Agreement
5. Novavax and Vivalis Sign a Research License Agreement to Use the EB66(R) Cell Line for the Production of Virus Like Particle Based Vaccines
6. Mach One Corporation Signs Definitive Agreement to Acquire Ceres Organic Harvest, Inc.
7. ProCure Signs Agreement with .decimal, Inc. to Purchase Patient-Specific Devices for Its Proton Therapy Center in Oklahoma City
8. Sigma-Aldrich Signs Agreement With CPC Scientific for the Distribution of PEPscreen(R) Custom Peptide Libraries
9. Netsmart University Announces Partner Referral Agreement With New York Association of Alcohol and Substance Abuse Providers
10. University of Helsinki and ASM International renew research agreement on atomic layer deposition
11. S*BIO and Tragara Announce an Exclusive Worldwide License Agreement for Novel Multi-kinase Inhibitor SB1317
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... ... July 29, 2015 , ... Asymmetrex, LLC ... progress in evaluating the full range of capabilities of its unique cache of ... cells perform the day-to-day renewal and repair of normal tissues and organs. This ...
(Date:7/28/2015)... July 28, 2015  PDL BioPharma, Inc. (PDL, or ... the Company will release its second quarter 2015 financial ... Wednesday, August 5, 2015, after market close. PDL,s management ... at 4:30 p.m. Eastern Time to discuss the financial ... be available via the webcast link on the PDL ...
(Date:7/28/2015)... 21, 2015 Research and Markets ( ... "Biomedical Refrigerators and Freezers Market - Global ... 2014 - 2022" report to their offering. ... freezers market has been segmented based on applications: ... and others. The others segment includes applications of ...
(Date:7/28/2015)... , July 28, 2015  Moerae Matrix Inc. ... 1 clinical trial with MMI-0100, a first-in-class inhibitor ... developed for pulmonary disorders characterized by inflammation and ... United Kingdom , is a double-blind, two-way ... the safety and tolerability of MMI-0100 when given ...
Breaking Biology Technology:Asymmetrex Plans to Report Results From Adult Stem Cell Technology Development Milestone Studies At End of Summer 2Asymmetrex Plans to Report Results From Adult Stem Cell Technology Development Milestone Studies At End of Summer 3Asymmetrex Plans to Report Results From Adult Stem Cell Technology Development Milestone Studies At End of Summer 4PDL BioPharma to Announce Second Quarter 2015 Financial Results on August 5, 2015 2Biomedical Refrigerators and Freezers Market Report - Global Industry Analysis 2015 2Biomedical Refrigerators and Freezers Market Report - Global Industry Analysis 2015 3Moerae Initiates Lipopolysaccharide (LPS) Challenge Study of Inhaled MMI-0100 for Pulmonary Disease Following Encouraging Safety and Tolerability Observed in Single Ascending Dose Phase 1 Study 2
... , ... Specialist Segmentation Module explores how oncologists use the Internet and other technologies for professional ... ... than the overall population of U.S. physicians to visit pharmaceutical, biotech, and device corporate ...
... , , , PHILADELPHIA, ... technologies for biomedical research, molecular diagnostics and personalized medicine, today ... have joined the company,s advisory team. Dr. Lee is ... at Brigham and Women,s Hospital, Harvard Medical School and the ...
... HOERSHOLM, Denmark and SAN DIEGO, California, September 16 /PRNewswire/,-- , ... Leading RNA Industry Expert,Art Levin Ph.D. as President of US ... - Utilizing its Proprietary RNA Chemistry - Locked Nucleic Acid ... Relationships,With New Partners, Increase Visibility With Capital Markets and Attract,Leading ...
Cached Biology Technology:Oncologists Visit Pharma Sites and Post Professional Content Online More Frequently than the Average Physician 2Oncologists Visit Pharma Sites and Post Professional Content Online More Frequently than the Average Physician 3Oncologists Visit Pharma Sites and Post Professional Content Online More Frequently than the Average Physician 4BioNanomatrix Appoints Genomic Research Experts Charles Lee and David L. Barker as Advisers 2BioNanomatrix Appoints Genomic Research Experts Charles Lee and David L. Barker as Advisers 3BioNanomatrix Appoints Genomic Research Experts Charles Lee and David L. Barker as Advisers 4New Collaborations and Breakthrough Advancements in RNA-Based Drug Development Programs Lead Santaris Pharma A/S to Establish US Operations 2New Collaborations and Breakthrough Advancements in RNA-Based Drug Development Programs Lead Santaris Pharma A/S to Establish US Operations 3New Collaborations and Breakthrough Advancements in RNA-Based Drug Development Programs Lead Santaris Pharma A/S to Establish US Operations 4
(Date:7/21/2015)... Today, ZTE announced its Android smartphone Axon, featuring FPC,s touch ... 2015 that relate to sales of FPC1025 for this smartphone model ... for 2015. Jörgen Lantto, CEO of FPC, comments: " ... China and we are proud that ZTE ... Axon , its first smartphone ...
(Date:7/13/2015)... Jul. 13, 2015 NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce ... patent 62/188684 for BEHAVIORAL-DIRECTED AUTHENTIATION METHOD ... convenient and secure method to make payments.  With ... methods, introduced with its groundbreaking voice-direct payment patent ...
(Date:7/8/2015)... 8, 2015 Summary Pancreatic cancer is ... most fatal, with a mortality rate of 10.9 deaths ... pancreatic cancer patients has highlighted a significant need for ... being met by the current market. A highly ... with varying molecule types and mechanisms of action, which ...
Breaking Biology News(10 mins):FPC's Touch Fingerprint Sensor FPC1025 in ZTE's Smartphone Axon 2NXT-ID Patents Behavior-Directed Payments 2NXT-ID Patents Behavior-Directed Payments 3NXT-ID Patents Behavior-Directed Payments 4Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3
... people are injured or die each year in hospitals ... hospital, depending on its size, about US$5.6 million every ... the personal costs of injuries to patients. , Nationally, ... hospital admission are enormous: between $1.6 billion and $5.6 ...
... designated a group of 13 tropical ... African Sleeping Sickness (African trypanosomiasis), Chagas ... (elephantiasis), Onchocerciasis (river blindness), Drancunculiasis (guinea ... Trachoma). , These diseases have much ...
... production of a protein called vasostatin may prove a promising ... of print in Gut. , Pancreatic cancer is the fifth ... is extremely difficult to treat. Only 3% of affected patients ... that has remained static for the past three decades. , ...
Cached Biology News:Is it Possible to Change Prescribing Habits? 2Is it Possible to Change Prescribing Habits? 3A New Era of Hope for the World's Most Neglected Diseases 2A New Era of Hope for the World's Most Neglected Diseases 3Gene therapy potential for treatment of pancreatic cancer 2
... , Customer Peptide Synthesis , 20 Amino Acid length ... 20 mg will return to customer for future usage conjugation ... , Maintenance 102 days/each , ... x5 /each , Test bleed (app. 5 ml) ...
Request Info...
... This Kit Contains the following: , Coated Capture ... sealers , Wash/Sample Diluent: 300 mL of 2X ... vial 10 microg lyophilized peptide , Lyophilized Standard ... of 50X concentrate , Secondary Antibody-HRP: 30 microL ...
...
Biology Products: